Drugs / Amniotic Membrane Extract
Amniotic Membrane Extract
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02649621 | Aug 2011 → Mar 2012 | limbal stem cell deficiency | Royan Institute | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02746848 | Jun 2014 → May 2015 | corneal disorder | Royan Institute | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05598242 | Feb → Sep 2019 | Sjogren syndrome, dry eye syndrome | Hospital Nacional Profesor Alejandro Posadas | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amniotic membrane extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05598242 ↗ |
| Known as | AMEED | “Amniotic membrane extract eye drops (AMEED)” NCT05598242 ↗2“Amniotic Membrane Extract Eye Drop (AMEED)” NCT02746848 ↗ “Amniotic Membrane Extract Eye Drop (AMEED)” NCT02649621 ↗ |
| Known as | Amniotic Membrane Extract Eye Drop | “Amniotic Membrane Extract Eye Drop (AMEED)” NCT02746848 ↗ |